title: Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.
abstract: The antibody responses to influenza virus A/PR/8/34 HA vaccine and protection against virus challenge in mice given the vaccine together with the B subunit of cholera toxin (CTB) intranasally were compared with those in mice given the vaccine with CTB perorally, intraperitoneally or subcutaneously. Intranasal vaccination induced remarkably higher levels of antiviral IgA antibodies in both respiratory washings and serum than did other routes of vaccination. The titres of antiviral IgG antibodies in respiratory washings and serum, and haemagglutination-inhibiting (HI) antibodies in serum, were similar after intranasal and parenteral vaccination. Oral vaccination, however, induced low levels of antiviral IgG antibodies but no detectable HI antibodies. Moreover, intranasal immunization elicited significantly higher titres of antiviral IgA antibodies in intestinal secretions in comparison with oral immunization. In contrast, parenteral immunization failed to induce these IgA antibodies. In virus challenge studies, a greater protective effect was seen after intranasal and intraperitoneal vaccination than after other routes of vaccination. These results suggest that intranasal inoculation of combined HA vaccine and CTB is superior to oral or parenteral inoculation in protecting mice. Furthermore, the intestinal antiviral IgA responses suggest that intranasal administration of CTB-combined vaccines could be effective not only against respiratory pathogens but also against enteropathogens.
authors.affiliation: Department of Pathology, National Institute of Health, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: H
authors.initials: H
authors.lastname: Kurata
authors.forename: H
authors.initials: H
authors.lastname: Funato
authors.forename: T
authors.initials: T
authors.lastname: Nagamine
authors.forename: C
authors.initials: C
authors.lastname: Aizawa
authors.forename: S
authors.initials: S
authors.lastname: Tamura
authors.forename: K
authors.initials: K
authors.lastname: Shimada
authors.forename: T
authors.initials: T
authors.lastname: Kurata
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D002772:Cholera Toxin / Q000008:administration & dosage*; D005260:Female; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000517:prevention & control
chemical_list: D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D002772:Cholera Toxin